[Alanineaminopeptidase excretion in the urine and osmotic neophropathy. Studies on the diagnostic meaning and pathophysiology of elevated alanineaminopeptidase excretion after use of radiologic contrast media for the kidneys].
In patients with several internal diseases the percental change of the excretion of the alanine aminopeptidase with the urine 18--20 hours after intravenous injection of the X-ray contrast medium Visotrast going through the kidneys correlates with the change after infusion of Mannitol (r = 0.98, p less than 0.001) and of Dextran (r = 0.82, p less than 0.01). The osmotic nephropathy is to be regarded as a common cause of an increased enzyme excretion, which appears after application of hypertonic solutions especially in preexisting renal diseases. While the excretion of alanine aminopeptidase in persons with healthy kidneys changes only unessentially, in patients with diffuse nephropathies after the application of these drugs there appear diagnostically relevant increases of excretion.
D000626:Aminopeptidases / Q000652:urine*; D003287:Contrast Media / Q000009:adverse effects*; D003911:Dextrans; D006801:Humans; D008353:Mannitol; D011704:Pyelonephritis / Q000503:physiopathology*; D012965:Sodium Chloride
D003287:Contrast Media; D003911:Dextrans; D008353:Mannitol; D012965:Sodium Chloride; D000626:Aminopeptidases
Alaninaminopeptidaseausscheidung mit dem Harn und osmotische Nephropathie Untersuchungen zur diagnostischen Bedeutung und Pathophysiologie der erhöhten Alaninaminopeptidaseausscheidung nach nierengängigen Röntgenkontrastmitteln